BioSpace News Archive

Cerecor Inc., a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, announced that Michael F. Cola, President and Chief Executive Officer, will present at two upcoming virtual conferences.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market.

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will be presenting at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31st Annual Healthcare Conference,

BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Thursday, March 11, 2021

Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Barclays Global Healthcare Conference

Wave Life Sciences today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update.

Registrational Phase 3 trial will assess measurable residual disease (MRD) negative complete response (CR) as the primary endpoint to support potential accelerated approval First time MRD could serve as the basis for regulatory approval in AML Trial to begin in mid-2021, with MRD negative CR data expected in second half of 2023

Skylight Health Group Inc (TSXV:SHG; OTCQX: SHGFF) (“Skylight Health” or the “Company”), one of the largest multi-specialty healthcare systems in the United States, is pleased to announce that it has entered into Letters of Intent (LOIs) to acquire 3 independent Primary Care practices in the United States, immediately adding over $10 million in revenue and positive EBITDA when closed

Eyepoint Pharmaceuticals today announced financial results for the fourth quarter and year ended December 31, 2020 and highlighted recent corporate developments.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.